Abstract: With the advent of new trends toward 'simplified therapy' for AIDS， the integrase strand transfer inhibitor (INSTI) regimens based on bictegravir or dolutegravir-specifically bikernipon tablets and lamivudine dolutegravir tablets -have emerged as core strategies spanning the entire continuum of AIDS treatment. The epidemiological characteristics of human immunodeficiency virus (HIV) infection， current status of antimicrobial resistance， chemical structures and advantages of the two drugs， their clinical applications， precautions for use， and drug-drug interactions were systematically elaborated in the article， and the aim is to compare treatment regimens based on bictegravir versus dolutegravir so as to provide critical comparative evidence and practical guidance for clinical decision-making.